Advertisement

Gastric Cancer

, Volume 21, Issue 5, pp 811–818 | Cite as

A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer with early relapse after S-1 adjuvant therapy: XParTS-I trial

  • Kazuhiro Nishikawa
  • Akira Tsuburaya
  • Takaki Yoshikawa
  • Masazumi Takahashi
  • Kazuaki Tanabe
  • Kensei Yamaguchi
  • Shigefumi Yoshino
  • Tsutomu Namikawa
  • Toru Aoyama
  • Yasushi Rino
  • Junji Kawada
  • Akihito Tsuji
  • Koichi Taira
  • Yutaka Kimura
  • Yasuhiro Kodera
  • Yoshinori Hirashima
  • Hiroshi Yabusaki
  • Naoki Hirabayashi
  • Kazumasa Fujitani
  • Yumi Miyashita
  • Satoshi Morita
  • Junichi Sakamoto
Original Article

Abstract

Backgrounds

In Japan, standard regimens for advanced gastric cancer (AGC) include S-1 chemotherapy. The standard treatment for early relapse after adjuvant chemotherapy with fluoropyrimidine alone is platinum-based chemotherapy, while the standard treatment for early relapse after adjuvant chemotherapy with fluoropyrimidine plus platinum is second-line chemotherapy. To evaluate the efficacy and safety of capecitabine plus cisplatin (XP) treatment for AGC patients who relapse within 6 months after S-1-based therapy, we conducted a multicenter phase II trial (NCT01412294).

Methods

HER2-negative gastric cancer patients treated with adjuvant chemotherapy including S-1 for more than 12 weeks and relapsed within 6 months were treated with capecitabine 1000 mg/m2 bid for 14 days plus cisplatin 80 mg/m2 on day 1 of a 3-week cycle. The primary endpoint was PFS; secondary endpoints were OS, time to treatment failure, overall response rate (ORR) and safety.

Results

Forty patients (median age 64) were enrolled; of those, 37 (92.5%) received adjuvant S-1 monotherapy. Median PFS was 4.4 months (95% CI 3.6–5.1), which was longer than the 2-month protocol-specified threshold (p < 0.001). Median OS was 13.7 months (95% CI 9.0–17.7) and ORR was 8/30 (26.7%) (95% CI 14.2–44.4). Most common grade ≥ 3 adverse events were neutropenia (23%), anemia (18%), elevated serum creatinine (18%), fatigue (13%), diarrhea (7.5%), and anorexia (7.5%).

Conclusions

XP was safe and effective in patients with early relapse after S-1 adjuvant chemotherapy for curatively resected gastric cancers. XP may be a good option for the treatment of patients after early failure after adjuvant S-1.

Trial registration

NCT01412294.

Keywords

Advanced gastric cancer Capecitabine plus cisplatin (XP) S-1 adjuvant therapy Early relapse Fluoropyrimidine switching 

Notes

Acknowledgements

We thank the investigators from the following institutions who enrolled patients for this trial: Osaka General Medical Center, Yokohama Municipal Citizen’s Hospital, Hiroshima University Graduate School of Medicine, Saitama Cancer Center, Yokohama City University, Yamaguchi University Graduate School of Medicine, Kochi Medical School, Kanagawa Cancer Center, Yokohama City University, Kobe City Medical Center General Hospital, Osaka City General Hospital, Sakai Municipal Hospital, Nagoya University Graduate School of Medicine, Oita University Faculty of Medicine, Hiroshima City Asa Hospital, and Niigata Cancer Center Hospital. Furthermore, we deeply appreciate all patients who participated in the trial. We acknowledge Dr Mark Abramovitz of Edanz Medical Writing for editorial support, which was funded by the non-profit organization Epidemiological and Clinical Research Information Network (ECRIN).

Funding

This work was supported by the non-profit organization Epidemiological and Clinical Research Information Network (ECRIN).

Compliance with ethical standards

Conflict of interest

The individual conflict of interest disclosure is as follows: K. Nishikawa has received honoraria from Chugai, Taiho, Yakult, Eli Lilly, Tsumura, and EA Pharma, and research funding from Yakult and Taiho, outside the submitted work. T. Yoshikawa has received lecture fees from Chugai, Taiho, Yakult, Eli Lilly and Ono, and for advisory work from Ono and MSD, outside the submitted work. K. Yamaguchi has received personal fees from Chugai, Taiho, Yakult, Takeda, Merck and Eli Lilly, and research funding from MSD, Merck, Bristol, Ono, Dainippon Sumitomo, Taiho, Daiichi-Sankyo and Yakult, outside the submitted work. S. Yoshino has received honoraria from Chugai, Taiho, Ono and Eli Lilly, outside the submitted work. Y. Kodera has received research funding from Chugai, Taiho, Daiichi-Sankyo, Bristol-Myers, Eli Lilly, Otsuka, Takeda, Yakult, CSL Behring, Pfizer, Ono, Kaken, Tsumura, EA Pharma, Novartis, KCI and the Japan Blood Products Organization, outside the submitted work. S. Morita has received honoraria from Chugai and Taiho, outside the submitted work. J. Sakamoto has received consultant fee from Takeda, and Honoraria from Tsumura and Chugai, outside the submitted work. None of the remaining authors have potential conflicts of interest to declare.

Ethical statements

This trial was conducted in compliance with the ethical principles of the Declaration of Helsinki and the Ethical Guidelines for Clinical Studies of the Japanese Ministry of Health, Labour and Welfare. This trial was approved by the institutional review boards or ethics committees at all participating centers. This trial was registered with ClinicalTrials.gov (NCT01412294).

References

  1. 1.
    Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.CrossRefPubMedGoogle Scholar
  2. 2.
    Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.CrossRefPubMedGoogle Scholar
  3. 3.
    Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387–93.CrossRefPubMedGoogle Scholar
  4. 4.
    Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009;10:1063–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–21.CrossRefPubMedGoogle Scholar
  6. 6.
    Shitara K, Morita S, Fujitani K, Kadowaki S, Takiguchi N, Hirabayashi N, et al. Combination chemotherapy with S-1 plus cisplatin for gastric cancer that recurs after adjuvant chemotherapy with S-1: multi-institutional retrospective analysis. Gastric Cancer. 2012;15:245–51.CrossRefPubMedGoogle Scholar
  7. 7.
    Kang HJ, Chang HM, Kim TW, Ryu MH, Sohn HJ, Yook JH, et al. Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy. Br J Cancer. 2005;92:246–51.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36–46.CrossRefPubMedGoogle Scholar
  10. 10.
    Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20:666–73.CrossRefPubMedGoogle Scholar
  11. 11.
    NCCN Guidelines Version 5. Gastric cancer NCCN evidence blocks. 2017. https://www.nccn.org/professionals/physician_gls/pdf/gastric_blocks.pdf. Accessed 4 Nov 2017.
  12. 12.
    Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.CrossRefPubMedGoogle Scholar
  13. 13.
    Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011;29:3968–76.CrossRefPubMedGoogle Scholar
  14. 14.
    Takiuchi H, Goto M, Imamura H, Furukawa H, Imano M, Imamoto H, et al. Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302). Jpn J Clin Oncol. 2008;38:176–81.CrossRefPubMedGoogle Scholar
  15. 15.
    Ono A, Boku N, Onozawa Y, Hironaka S, Fukutomi A, Yasui H, et al. Activity of S-1 in advanced or recurrent gastric cancer patients after failure of prior chemotherapy, including irinotecan + cisplatin or fluorouracil (except S-1). Jpn J Clin Oncol. 2009;39:332–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur-0.4M gimestat-1M otastat potassium) in advanced gastric cancer patients. Eur J Cancer. 1998;34:1715–20.CrossRefPubMedGoogle Scholar
  17. 17.
    Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology. 2000;58:191–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998;34:1274–81.CrossRefPubMedGoogle Scholar
  19. 19.
    Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010;28:1547–53.CrossRefPubMedGoogle Scholar
  20. 20.
    Yamada Y, Yamamoto S, Ohtsu A, Suzuki Y, Nasu J, Yamaguchi K, et al. Impact of dihydropyrimidine dehydrogenase status of biopsy specimens on efficacy of irinotecan plus cisplatin, S-1, or 5-FU as first-line treatment of advanced gastric cancer patients in JCOG9912. ASCO Meet Abstr. 2009;27(15s):4535.Google Scholar
  21. 21.
    Koizumi W, Okayasu I, Hyodo I, Sakamoto J, Kojima H. Prediction of the effect of capecitabine in gastric cancer by immunohistochemical staining of thymidine phosphorylase and dihydropyrimidine dehydrogenase. Anticancer Drugs. 2008;19:819–24.CrossRefPubMedGoogle Scholar
  22. 22.
    Ichikawa W, Takahashi T, Suto K, Hirayama R. Gene expressions for thymidylate synthase (TS), orotate phosphoribosyltransferase (OPRT), and thymidine phosphorylase (TP), not dihydropyrimidine dehydrogenase (DPD), influence outcome of patients (pts) treated with S-1 for gastric cancer (GC). J Clin Oncol (Meet Abstr) ASCO Meet Abstr. 2004;22(14_suppl):4050.Google Scholar
  23. 23.
    Napieralski R, Ott K, Kremer M, Specht K, Vogelsang H, Becker K, et al. Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients. Clin Cancer Res. 2005;11:3025–31.CrossRefPubMedGoogle Scholar
  24. 24.
    Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol. 2013;31:4438–44.CrossRefPubMedGoogle Scholar
  25. 25.
    Higuchi K, Tanabe S, Shimada K, Hosaka H, Sasaki E, Nakayama N, et al. Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: a randomised phase III trial (TCOG GI-0801/BIRIP trial). Eur J Cancer. 2014;50:1437–45.CrossRefPubMedGoogle Scholar
  26. 26.
    Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 2014;15:78–86.CrossRefPubMedGoogle Scholar

Copyright information

© The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2018

Authors and Affiliations

  • Kazuhiro Nishikawa
    • 1
  • Akira Tsuburaya
    • 2
  • Takaki Yoshikawa
    • 3
  • Masazumi Takahashi
    • 4
  • Kazuaki Tanabe
    • 5
  • Kensei Yamaguchi
    • 6
  • Shigefumi Yoshino
    • 7
  • Tsutomu Namikawa
    • 8
  • Toru Aoyama
    • 3
  • Yasushi Rino
    • 9
  • Junji Kawada
    • 10
  • Akihito Tsuji
    • 11
  • Koichi Taira
    • 12
  • Yutaka Kimura
    • 13
  • Yasuhiro Kodera
    • 14
  • Yoshinori Hirashima
    • 15
  • Hiroshi Yabusaki
    • 16
  • Naoki Hirabayashi
    • 17
  • Kazumasa Fujitani
    • 10
  • Yumi Miyashita
    • 18
  • Satoshi Morita
    • 19
  • Junichi Sakamoto
    • 20
  1. 1.Department of SurgeryOsaka National HospitalOsakaJapan
  2. 2.Department of SurgeryTsuboi Cancer Center HospitalKoriyamaJapan
  3. 3.Department of Gastrointestinal SurgeryKanagawa Cancer CenterYokohamaJapan
  4. 4.Department of SurgeryYokohama Municipal Citizen’s HospitalYokohamaJapan
  5. 5.Department of Gastroenterological and Transplant SurgeryHiroshima UniversityHiroshimaJapan
  6. 6.Division of GastroenterologySaitama Cancer CenterKita-Adachi-GunJapan
  7. 7.Oncology CenterYamaguchi University HospitalUbeJapan
  8. 8.Department of Surgery IKochi Medical SchoolNankokuJapan
  9. 9.Department of SurgeryYokohama City UniversityYokohamaJapan
  10. 10.Department of SurgeryOsaka General Medical CenterOsakaJapan
  11. 11.Department of Clinical OncologyKobe City Medical Center General HospitalKobeJapan
  12. 12.Department of GastroenterologyOsaka City University Graduate School of MedicineOsakaJapan
  13. 13.Department of Surgery, Faculty of MedicineKindai UniversityOsakasayamaJapan
  14. 14.Department of Gastroenterological SurgeryNagoya University Graduate School of MedicineNagoyaJapan
  15. 15.Department of Medical Oncology and Hematology, Faculty of MedicineOita UniversityOitaJapan
  16. 16.Department of Gastroenterological SurgeryNiigata Cancer Center HospitalNiigataJapan
  17. 17.Department of SurgeryHiroshima City Asa HospitalHiroshimaJapan
  18. 18.Epidemiological and Clinical Research Information Network (ECRIN)OkazakiJapan
  19. 19.Department of Biomedical Statistics and Bioinformatics, Graduate School of MedicineKyoto UniversityKyotoJapan
  20. 20.Tokai Central HospitalKakamigaharaJapan

Personalised recommendations